<DOC>
	<DOCNO>NCT02335879</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety Domestic Recombinant Human Follitropin ( Gonal-F ) Injection treatment WHO â…¡ anovulation ( include polycystic ovarian syndrome [ PCOS ] subject ) .</brief_summary>
	<brief_title>Phase III Clinical Study Domestic Recombinant Human Follitropin Injection Treat WHO Class II Anovulation</brief_title>
	<detailed_description />
	<mesh_term>Anovulation</mesh_term>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<criteria>Married infertile woman age 2138 . BMI &lt; 28kg/m2 . According detection level serum estradiol ( E2 ) , prolactin ( PRL ) , progesterone ( P ) , testosterone ( T ) , luteinizing hormone ( LH ) , follicle stimulate hormone ( FSH ) , subject diagnose WHO class II anovulation oligoovulation , hormone level subject normal normal treatment begin study , FSH &lt; 10IU/L . Bilateral fallopian tube unobstructed proved hysterosalpingograph laparoscopic examination within one year , history abortion pelvic infection examination , researcher decide whether examination need repeat . If subject salpingoplasty laparoscope , bilateral fallopian tube unobstructed surgery , need hysterosalpingograph . If confirm , must do prove bilateral fallopian tube unobstructed . Vaginal Bultrasound examination show ovarian pathological tumor , hysteromyoma hysteromyoma &lt; 4cm , affect endometrial function . Two examination spouse semen normal within six month , comply IUI standard . No history drug abuse . Voluntarily sign inform consent form agree medication accept evaluation accord requirement research protocol . The subject use gonadotropin therapy within past three month ( regardless result treatment ) . The uterine factor affect pregnancy tumor . Pregnancy contraindication , genetic disease , mental disease , drug abuse , sexually transmit disease , severe heart disease hepatic kidney function insufficiency . Obscure vaginal bleeding . Subjects allergic application FSH/HMG HCG past . Other condition researcher think suitable clinical trial .</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>38 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>